Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

August 12, 2019

Primary Completion Date

March 5, 2020

Study Completion Date

March 19, 2020

Conditions
Anthrax
Interventions
DRUG

Ciprofloxacin 500Mg Tablet

Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 4-9, 22-24 and 31-37.

DRUG

Doxycycline 100Mg Tablet

Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38.

BIOLOGICAL

AV7909

0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.

Trial Locations (4)

32720

Avail Clinical Research, LLC, DeLand

37920

New Orleans Center for Clinical Research / Volunteer Research Group, Knoxville

64114

The Center for Pharmaceutical Research, Kansas City

68134

Meridian Clinical Research, LLC, Omaha

Sponsors
All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Emergent BioSolutions

INDUSTRY